Xeris Biopharma (NASDAQ:XERS) Insider Sells $156,827.06 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of Xeris Biopharma stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $9.41, for a total value of $156,827.06. Following the sale, the insider owned 1,111,130 shares of the company’s stock, valued at approximately $10,455,733.30. This represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Tuesday, September 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total transaction of $141,494.34.
• On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.01, for a total transaction of $133,494.66.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $9.08 on Monday. The stock has a market capitalization of $1.66 billion, a P/E ratio of -82.55 and a beta of 0.53. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $11.33. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The firm’s 50-day moving average is $8.46 and its two-hundred day moving average is $7.32.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on XERS shares. Leerink Partners increased their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Barclays upped their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $12.80.

Institutional Trading of Xeris Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC purchased a new position in Xeris Biopharma in the second quarter valued at about $74,000. Allworth Financial LP boosted its position in shares of Xeris Biopharma by 86.4% in the second quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after buying an additional 2,000 shares during the period. Allianz Asset Management GmbH acquired a new stake in shares of Xeris Biopharma in the second quarter valued at about $314,000. Corient Private Wealth LP acquired a new stake in shares of Xeris Biopharma in the second quarter valued at about $1,458,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $89,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.